Evidence map›Paper›PMID 29914529›Full record

ArticleWorld journal of surgical oncology2018

Letter to the editor: is HIF-1α a viable prognostic indicator in OSCC? A critical review of a meta-analysis study.

Rama Jayaraj, Chellan Kumarasamy, Madhav Madurantakam Royam, Arikketh Devi, Siddharta Baxi

Open access · goldAbstract readCommentLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Rama JayarajCollege of Health and Human Sciences, Charles Darwin University, Ellengowan Drive, Darwin, Northern Territory, 0909, Australia. Rama.Jayaraj@cdu.edu.au.ORCID 0000-0002-2179-0510
Chellan KumarasamyDepartment of Genetic Engineering, Kattankulathur Campus, SRM Institute of Science and Technology, Chennai, Tamil Nadu, 603203, India.
Madhav Madurantakam RoyamSchool of Bio-Sciences and Technology, Vellore Institute of Technology (VIT), Vellore, Tamil Nadu, 632014, India.
Arikketh DeviDepartment of Genetic Engineering, Kattankulathur Campus, SRM Institute of Science and Technology, Chennai, Tamil Nadu, 603203, India.
Siddharta BaxiGenesis Cancer Care, Bunbury, Western Australia, 6230, Australia.
SRM Institute of Science and Technology · INCharles Darwin University · AULishman Health Foundation · AUVellore Institute of Technology University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study performed by Zhou et al. (World J Surg Oncol 15:104, 2017) titled "Clinical and prognostic significance of HIF-1α overexpression in oral squamous cell carcinoma: a meta-analysis" attempts to highlight hypoxia-inducible factor-1 alpha as a possible prognostic marker in oral squamous cell carcinoma (OSCC). We would like to underline a few points which may affect such a conclusion. The correlations between HIF-1α expression and tumour size as well as tumour stage are debatable. Further, the subgroup analysis incorporating Australia and Europe into a single subgroup limits the viability of the prognostic analysis of HIF-1α. We also suggest future studies in the same research area to analyse head and neck squamous cell carcinoma instead of OSCC, to ameliorate the limitations encountered by Zhou et al., due to the scarcity of relevant clinical data and a low number of studies about OSCC.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsMouth NeoplasmsSquamous Cell Carcinoma of Head and NeckHumansPrognosisHIF-1αLetter to the editorOral squamous cell carcinomaPrognosis

Identifiers

PMID29914529
PMCPMC6006741
OpenAlexW2809185893

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.